Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2021 | Pembrolizumab versus high-dose interferon or ipilimumab in high-risk resected melanoma

Pauline Funchain, MD, Cleveland Clinic, Cleveland, OH, shares findings from the intergroup S1404 Phase III trial (NCT02506153) comparing pembrolizumab to high-dose interferon or ipilimumab in patients with high-risk resected melanoma. The analysis aimed to assess if adjuvant pembrolizumab would offer overall survival or relapse-free survival (RFS) benefits in comparison to the two FDA-approved adjuvant treatment options. The results from over 1300 patients demonstrated that pembrolizumab elicited a statistically significant improvement in RFS compared to either high-dose interferon or ipilimumab. No statistically significant improvement in overall survival was shown in the pembrolizumab arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Pauline Funchain, MD has received research funds from Pfizer and BMS.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.